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Atrial high rate episodes (AHREs) are defined as asymptomatic atrial tachyarrhyth-
mias detected by cardiac implantable electronic devices with atrial sensing, provid-
ing automated continuous monitoring and tracings storage, occurring in subjects
with no previous clinical atrial fibrillation (AF) and with no AF detected at conven-
tional electrocardiogram recordings. AHREs are associated with an increased
thrombo-embolic risk, which is not negligible, although lower than that of clinical
AF. The thrombo-embolic risk increases with increasing burden of AHREs, and more-
over, AHREs burden shows a dynamic pattern, with tendency to progression along
with time, with potential transition to clinical AF. The clinical management of
AHREs, in particular with regard to prophylactic treatment with oral anticoagulants
(OACs), remains uncertain and heterogeneous. At present, in patients with confirmed
AHREs, as a result of device tracing analysis, an integrated, individual and clinically-
guided assessment should be applied, taking into account the patients’ risk of stroke
(to be reassessed regularly) and the AHREs burden. The use of OACs, preferentially
non-vitamin K antagonists OACs, may be justified in selected patients, such as those
with longer AHREs durations (in the range of several hours or 24 h), with no doubts
on AF diagnosis after device tracing analysis and with an estimated high/very high
individual risk of stroke, accounting for the anticipated net clinical benefit, and in-
formed patient’s preferences. Two randomized clinical trials on this topic are cur-
rently ongoing and are likely to better define the role of anticoagulant therapy in
patients with AHREs.
Clinical atrial fibrillation: definition and
symptoms assessment
Atrial fibrillation (AF) is the most common cardiac arrhyth-
mia and its prevalence is expected to increase in the next
years, also in relationship with progressive population
ageing.1,2
It is important to precise the definition of clinical AF.
According to Guidelines3–5 any arrhythmia that has
the electrocardiogram (ECG) characteristics of AF and lasts
sufficiently long for a 12-lead ECG to be recorded, or at
least 30 s on a rhythm strip, should be considered as clinical
AF. The presence of arrhythmia-related symptoms is not
required for the definition of clinical AF, which therefore
can be symptomatic or asymptomatic.
The true epidemiological burden of AF is largely unknown
since an important proportion of patients may present
*Corresponding author. Tel: þ39 059 4225836, Fax: þ39 059 4224498,
Email: giuseppe.boriani@unimore.it
Published on behalf of the European Society of Cardiology. VC The Author(s) 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in
any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal Supplements (2020) 22 (Supplement O), O42–O52










42/6043870 by guest on 20 January 2021
asymptomatic AF or may present with non-specific symp-
toms.6,7 Despite continuous improvements in prevention,
diagnosis and treatment of AF, morbidity and mortality as-
sociated with AF are still high, especially in the elderly
population.8–10 Nowadays, physicians should acknowledge
that a considerable proportion of AF episodes are
completely asymptomatic. These episodes may or may not
be detected at the time of occurrence of a clinical event
(even at the time of stroke or systemic thromboembolism,
etc.) or by chance during occasional checks, with still some
resistance to institution of an appropriate prophylaxis with
oral anticoagulants (OACs) in patients at risk.8,11,12
Asymptomatic atrial fibrillation:
epidemiological and clinical implications
The proportion of AF that is asymptomatic is not well de-
fined, but reported rates vary from 10% to 40%, depending
on patient populations and settings, especially in terms of
patient age, prevalence of risk factors for AF, methods for
AF detection, and length of patient follow-up dura-
tion.6,7,12–14 Many studies indicate that asymptomatic AF is
more common among male subjects and when AF is non-
paroxysmal.11,13 In a clinical perspective, a key question is
if asymptomatic AF carries a lower risk of thrombo-embolic
events as compared to symptomatic AF. According to a se-
ries of studies, the implications in terms of outcomes, and
specifically in terms of risk of stroke, are even worse for
asymptomatic AF than for symptomatic AF.6,13,15
Therefore, the presence/absence of symptoms should not
interfere with prescription of OACs in patients considered
at risk according to the CHA2DS2VASc score.
4,5,16,17
Conversely, assessment of presence/absence of symp-
toms and evolution of symptoms along with time, usually
through grading according to the European Heart Rhythm
Association (EHRA) score, is important for defining the
most appropriate treatment strategy in terms of rate/
rhythm control.4,18,19 Despite some heterogeneity, the
results of a meta-analysis of six studies (two randomized
clinical trials and four observational studies) show no dif-
ferences in stroke/thromboembolism between asymptom-
atic and symptomatic AF and therefore the former (more
frequently associated with male sex) should not be
addressed differently in terms of stroke prevention and
other cardiovascular prevention therapies.20
Detection of patients with unknown, untreated asymp-
tomatic AF is the basis for initiatives of AF screening, tar-
geted to appropriate antithrombotic prophylaxis in
patients with untreated AF at risk of stroke.9,10,21
Atrial high rate episodes/subclinical AF:
definitions and characterization
Cardiac implantable electronic devices (CIEDs) have under-
gone considerable technological progress in the last deca-
des with possibility to treat bradycardia through implanted
pacemakers (PM), ventricular tachyarrhythmias through
implantable cardioverter-defibrillators (ICDs) and heart
failure in appropriately selected patients through devices
(PMs or ICDs) for cardiac resynchronization (CRT). CIEDs
are now capable to analyse, record and possibly treat dif-
ferent types of arrhythmias through one or more intracavi-
tary catheters.11,15,21,22 Furthermore, the atrial lead
allows us to continuously monitor the atrial activity and re-
cord any arrhythmic episode characterized by a high atrial
rate, named atrial high rate episodes (AHREs) (Figure 1).
Therefore, a key characteristics of AHREs episodes is
that they are recorded exclusively through the continuous
monitoring of CIEDs and include various atrial arrhythmias
such as AF, atrial flutter and atrial tachycardias, often with
transition from regular to irregular rhythm in the same pa-
tient, with recordings that can be stored in devices’ mem-
ory, as intracavitary electrograms (EGMs) (Figure 1).
At present, there is no consensus on which is the most
appropriate definition of AHRE, both in terms of duration
and atrial frequency of the episode. The definition adopted
by the majority of the studies in literature and by the
guidelines of the European Society of Cardiology (ESC) sets
the time limit of 5–6min and an atrial rate175 b.p.m.5
These cut-offs aim at minimizing the possible inclusion
of artefacts, since some episodes of high atrial frequency
may not represent an atrial arrhythmia of clinical interest,
but could simply be noise signals recorded by the atrial
lead.22,23
The term ‘subclinical AF’ and AHRE have been used in lit-
erature interchangeably, but a precise definition is
needed. According to consensus document and guide-
lines,5,22 the following definitions should be used:
• AHRE refers to events characterized by an atrial rate
above a programmed cut-off (>175 b.p.m., with a du-
ration of at least 5 min) detected by CIEDs with atrial
sensing (atrial lead/atrial sensing features) that allows
automated continuous monitoring of atrial rhythm and
tracings storage. The tracings of CIED-recorded AHREs
need to be checked for confirmation of its arrhythmic
nature in order to exclude artefacts/double counting
or repetitive non-reentrant ventriculo-atrial (VA) syn-
chrony resulting in false positives detections.
• Subclinical AF refers to AHRE confirmed to have the
characteristic of an atrial tachyarrhythmia (AF, atrial
flutter, atrial tachycardia) or AF episodes detected by
insertable cardiac monitors or wearable monitors and
confirmed by analysis of intracardiac electrograms or
ECG-recorded rhythm.
Despite some variable use occurred in literature, a key
component of AHRE/subclinical AF is the occurrence in sub-
jects with no previous detection of clinical AF (i.e. without
surface ECG tracings showing AF) and without symptoms
attributable to AF.
AHRE/subclinical AF: dynamic
characteristics, incidence, and relationship
with clinical AF
The concept of AHRE has raised some concern in the cardi-
ology community since in this term are included different
forms of atrial tachyarrhythmias, with a wide range of
atrial cycles (from regular atrial tachycardias to fast AF)
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and different patterns of organization of the atrial rhythm,
with frequent transitions from one pattern to another, as
demonstrated by studies performed in patients with dual-
chamber PMs with dedicated algorithms capable to detect
phases with regular, slower atrial rhythm susceptible to
termination by pacing24–26 (Figure 1). Moreover, as empha-
sized by guidelines,5 in case of AHRE detected by a CIED, it
is needed to validate the arrhythmia through device diag-
nostics, by analysis of the EGMs stored in device memory, in
order to rule-out a series of events leading to oversensing
and that do not correspond to a true atrial tachyarrhyth-
mias, such as repetitive non-reentrant VA synchrony, PM-
mediated tachycardia, far-field R wave oversensing, myo-
tonic potentials, lead failure, electromagnetic interfer-
ence, or other non-cardiac signals.15,23
The term ‘AF burden’ has been introduced in the most
recent years to describe the temporal pattern of AF and
atrial tachyarrhythmias, in terms of presence and duration
of arrhythmic episodes corresponding to AHRE/subclinical
AF, as detected by continuous monitoring with an
implanted device. ‘AF burden’ is now specifically defined
as the overall time spent in AF during a specified period of
time (usually 24h).5,15,23
In patients with a CIED, the incidence of AHRE, after an
average follow-up of 1 year, is usually estimated to be
around 20%.22 However, it is difficult to report precise esti-
mates of the true incidence and prevalence of AHREs be-
cause of the heterogeneity of the studies in literature in
terms of definition of AHREs, specific design (retrospective
or prospective), duration of follow-up, sample size, CIEDs
recognition algorithms, etc.27 In a wider perspective, tak-
ing into account all the data reported in literature, the in-
cidence of AHRE>5min can be considered to vary between
10% and 68%.28,29 As a matter of fact, as shown in Figure 2,
a considerable variability between the cohorts of patients
analysed has to be considered, since some studies included
groups of unselected patients with common indications for
PM/ICD implantation, while others included only subgroups
of patients at high risk of thrombo-embolic events and
some studies included also patients with previous history of
AF.30–40 Bearing in mind these findings, and the subsequent
reports from the literature, there is evidence that subclini-
cal AF episodes are common in patients implanted with
CIEDs, both in terms of incidence and prevalence.15,22,28
In the Asymptomatic Atrial Fibrillation and Stroke
Evaluation in Pacemaker Patients and the Atrial Fibrillation
Reduction Atrial Pacing Trial (ASSERT), subclinical atrial
tachyarrhythmias with at least 6min duration were
detected within 3months in around 10% of patients
implanted with a CIED with no previous history of clinical
AF.35 During a follow-up period of 2.5 years, additional sub-
clinical atrial tachyarrhythmias occurred in around 25% of
patients and around 16% of those who had subclinical atrial
tachyarrhythmias developed symptomatic AF.35
These findings highlight an interesting and clinically im-
portant aspect of AHREs. Indeed, AF burden and AHRE du-
ration show a dynamic pattern, with tendency to
progression along with time and transition from burden in
the range of minutes-few hours to 12–23h and even more
than 23h.41 In a study that enrolled 6580 patients, new AF
with an AF burden of5min was detected in 2244 patients
(34%) during a mean follow-up of 2.4 years and around half
of these patients transitioned to a higher AF-burden
threshold during follow-up. A higher duration of daily AF
burden manifested at first detection and a CHADS2 score
2 were factors significantly associated with faster transi-
tion to a subsequent higher burden. Approximately one-
fourth of the patients transitioned from a lower threshold
to a daily AF burden of 23 h during follow-up.41
Diederichsen et al.42 studied 590 individuals undergoing
continuous monitoring via loop recorder, aged 70years
with no history of clinical AF and with at least one of the
following risk factors: arterial hypertension, diabetes, pre-
vious stroke, or heart failure. A total of 205 (35%) subjects
Figure 1 Atrial high rate episode (AHRE) detected by a dual-chamber pacemaker and the corresponding intracavitary electrogram (EGM).
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developed AHREs lasting 6min and 33 (16%) of these
patients progressed to AHREs>24h.42
Therefore, in daily clinical practice, it is not uncommon
to document the dynamic nature of AHREs and also the pro-
gression of these episodes to clinical AF. In the meta-
analysis by Mahajan et al.27 taking into account the ancil-
lary study of the MOde Selection Trial (MOST)30 and the
ASSERT study,35 the risk of development of clinical AF in
patients with AHRE was quantified as being 5.66-fold
higher than patients without AHREs (Figure 3).
Of note, progression of AF burden should be interpreted
similarly to the progression of clinical AF12,43 being related
to a progressively advancing atrial structural remodelling
and worsening of underlying atrial cardiomyopathy.10,44
Clinical implications of AHRE/subclinical AF
with regard to adverse outcomes and stroke
An assessment of the clinical implications of AHRE, after
careful exclusion of oversensing, has to consider the dura-
tion of AHRE and the extent of AF burden. AHREs with a
very short duration, ranging from three atrial premature
complexes to 15–20 s, corresponding to non-sustained atrial
tachyarrhythmias, are currently considered of no specific
clinical significance since in the Registry of Atrial
Tachycardia and Atrial Fibrillation Episodes (RATE) during a
follow-up of 23months were found not significantly associ-
ated with episodes of longer duration, nor with an in-
creased risk of adverse clinical events (including death or
hospitalizations) nor with a significantly increased risk of
stroke/systemic thromboembolism.45
While most of the interest on the prognostic significance
of AHREs >5–6min has been focused on the risk of stroke,
the association with other outcomes should not be ignored.
A study from the USA including 224 patients with no history
of AF implanted with a dual-chamber PM found that AHREs
were associated, even after adjustment for age, sex, and
cardiovascular diseases, with a 2.8-fold increase in the risk
of cardiovascular mortality.46 A more recent study from UK
found that AHREs are associated with the risk of major ad-
verse cardiovascular events (including acute heart failure,
myocardial infarction, cardiovascular hospitalization, ven-
tricular tachycardia/fibrillation,) during long-term follow-
up and that the risk was higher in patients with AHRE
24h, as compared to patients with AHREs 5min.47
Similarly, in a sub-analysis of the ASSERT study, Wong et
al.48 evaluated 415 patients with AHREs lasting between
6min and 24h and noted that over a mean follow-up of
2 years, 15.7% of patients transitioned to AHREs >24h or
clinical AF. Furthermore, the hospitalization rate for heart
failure among patients with AHREs progression was higher
than that of patients without progression (8.9% per year vs.
2.5% per year) and the progression of AHREs was indepen-
dently associated with hospitalizations for heart failure
even after multivariable adjustment [hazard ratio (HR):
4.58]. Similar results were obtained even when patients
with prior history of heart failure were omitted from the
analysis (HR: 7.06), or when AHREs progression was limited
to>24 h alone, without clinical AF (HR: 3.68).48
Several studies investigated the risk of stroke associated
with AHREs and in a general view it is clear that patients
with AHREs have a high thrombo-embolic risk which, al-
though possibly lower than that related to clinical AF, is
certainly not negligible.
Figure 4 shows the HR for the risk of stroke in patients
with AHRE when compared with patients with no AHRE or
AHRE below the threshold and the observed actual rate of
stroke/systemic embolism in studies from the litera-
ture.30,32,35–37,39,49 Glotzer et al.30 in a retrospective,
Figure 2 Incidence of CIED-detected AHREs on the basis of data from literature (refs30–40). AF, atrial fibrillation; AHRE, atrial high-rate episode; CIED,
cardiac implanted electronic device; SVT, supraventricular tachycardia.









42/6043870 by guest on 20 January 2021
ancillary study of the MOST based on 312 patients, found
that patients with AHREs were at increased risk to develop
clinical AF [HR 5.93, 95% confidence interval (CI) 2.88–
12.2], to experience a non-fatal stroke or to die (HR 2.79,
95% CI 1.51–5.15) than patients without AHREs. Of note,
60% of patients included in the analysis had previous supra-
ventricular arrhythmias. In 2012, the ASSERTstudy showed
that the presence of AHREs was a predictor of stroke or sys-
temic embolism even after adjusting the analysis for known
stroke predictors (HR 2.5; 95% CI 1.28–4.89).35 In this pro-
spective, multicentre, observational study, 2580 patients
with no history of AF were enrolled. AHREs were defined as
atrial rate 190/min, lasting 6min and the average
follow-up was 2.5 years.35 Numerous further evidences
Figure 3 (A) Association between subclinical and clinical AF. (B) Association of subclinical atrial fibrillation and stroke risk. From Mahajan et al.,27 with
permission. AF, atrial fibrillation; AHRE, atrial high-rate episode.
Figure 4 Risk of stroke in patients with AHREs when compared with patients with no AHREs or AHREs below the threshold and the observed actual rate
of stroke/systemic embolism in studies from the literature (refs.30,32,35–37,39,49). AHRE, atrial high rate episode.
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support the hypothesis that AHREs are related to a higher
risk of thrombo-embolic events. In 2012, Shanmugam et al.
(Home Monitor CRT study)36 reported that, in a population
of 560 heart failure patients with CRT device, patients with
AHREs >3.8 h (atrial rate > 180/min) were 9.4 times more
likely to develop thrombo-embolic events than patients
without AHREs (P¼ 0.006) (32% of patients included in the
study had previous episodes of AF). Interesting results have
been reported by Benezet-Mazuecos et al.50 who showed
that AHREs (defined as atrial rate  225/min, duration 
5min) are an independent predictor of silent ischaemic
stroke (HR 9.76, 95% CI 1.76–54.07), (31% of the patients in-
cluded in the study had previous episodes of AF).
The TRENDS study (A Prospective Study of the Clinical
Significance of Atrial Arrhythmias Detected by Implanted
Device Diagnostics)34 prospectively evaluated 2486
patients with an implantable electronic device and CHADS2
 1. They found that the risk of annual thrombo-embolic
events was approximately two-fold higher in patients with
a high burden of AHREs (defined as 5.5h) compared to
patients with a low (<5.5 h) or zero burden (2.4% vs. 1.1%
per year; HR 2.20, 95% CI 0.96–5.05).34
A large dataset of patients with CIED-detected AHREs
was collated in the SOS (Stroke preventiOn Strategies) AF
project a pooled analysis of data from three prospective
studies (PANORAMA, Italian Clinical Services Project, and
TRENDS), with a total of 10 016 patients.37 During a median
follow-up of 24months, 43% of patients with implanted
devices experienced 1day with 5min of AHRE burden.
In a Cox regression analysis adjusted for CHADS2 score and
use of anticoagulants at baseline, AHRE burden was an in-
dependent predictor of stroke. In a dichotomized analysis
that compared various potential cut-off thresholds for
AHRE burden (5min, 1 h, 6 h, 12 h, and 23 h) a 1-h threshold
of AHRE burden was associated with an HR for ischaemic
stroke of 2.11 (95% CI 1.22–3.64, P¼ 0.008).37 In any case,
the absolute risk of ischaemic stroke in patients with AHREs
was low (0.39% annual rate in the whole cohort). Also, in a
Japanese study conducted by Kawakami et al.51 AHREs
with atrial rate 175/min and duration 5min were asso-
ciated with stroke or systemic embolism especially in the
subgroup of patients with high thrombo-embolic risk
(CHADS2 score >2), (HR 3.73, 95% CI 1.06–13.1). In this
study,51 around one-fourth of the patients had history of AF
and, indeed, it has to be stressed that one of the main limi-
tation of the majority of studies on AHREs is the inclusion
of patients with a history of previous clinical AF (Figure 2),
thus making it difficult to evaluate the effect of AHREs
alone on thrombo-embolic risk.
Rather than the duration of the arrhythmic episode it-
self, it seems to be the quantity of such episodes in a given
period of time, expressed precisely as arrhythmic burden,
to be a factor associated with the stroke risk.5,15,23 In a
study by Turakhia et al.,52 9850 patients with CIEDs re-
motely monitored in the Veterans Administration Health
Care System between 2002 and 2012 were analysed, focus-
ing on 187 patients with acute ischaemic stroke and contin-
uous heart rhythm monitoring through an implantable
cardiac device for 120days before the stroke. The presence
of AHREs >5.5 h was found associated with an increased
risk of stroke. The results from a sub-analysis of the ASSERT
study are slightly different instead.53 In fact, the thrombo-
embolic risk of the 2455 patients analysed in this trial was
actually increased only for episodes of AHREs >24h (HR
3.24, 95% CI 1.51–6.95), while the increase in stroke risk
was not significant for AHREs between 6min and 24h.53
The studies by Capucci et al.32 and Botto et al.49 offered
additional information, also in relationship with clinical
risk stratification. The first32 followed 725 patients with
dual-chamber pace-makers for a median follow-up of
22months, showing that the embolic risk was approxi-
mately three times higher in patients with AHREs >24h
(HR 3.1, 95% CI 1.1–10.5) while it was not for AHREs <24h.
The second,49 on the other hand, evaluated a cohort of 568
patients with dual-chamber PMs, divided into subgroups
based on the CHADS2 score and AF burden. It emerged that
patients with AHREs >5min and CHADS2 2, or AHREs
>24h and CHADS2 1 had a much higher annualized risk of
thrombo-embolic events than patients with AHREs <5min
and CHADS2 2, or AHREs <24h and CHADS2 1, or AHREs
>24h and CHADS2¼ 0 (5% vs. 0.8%; P¼ 0.035).
An overall assessment of the relationship between
device-detected AF burden is available in the meta-
analysis published by Mahajan et al.27 where after a sys-
tematic review of all the literature on AHRE available up to
2016, the annual stroke rate in patients with subclinical AF
with a burden higher than the cut-off duration employed in
the specific study (varying from 5min to 24h) was 1.89/
100 person-year, with a 2.4-fold increased risk of stroke as
compared to patients with subclinical AF below the cut-off
duration (absolute risk was 0.93/100 person-year)
(Figure 3).
In addition, the availability in CIEDs of continuous moni-
toring of the atrial rhythm, extended to periods of months/
years, has allowed to obtain a detailed picture of the tem-
poral relationships between occurrence of AHREs/subclini-
cal AF episodes, and occurrence of ischaemic stroke/
systemic thromboembolism.23 Many studies evaluating
patients implanted with a CIED, with or without previous
atrial tachyarrhythmias, highlighted that ischaemic stroke
may occur without a strict temporal correlation with epi-
sodes of atrial tachyarrhythmias, in terms of presence of
AHREs/subclinical AF at the time of stroke or in the days
before.15,54,55
Clinical management of the risk of stroke
associated with AHREs
The categorization, clinical characterization, and manage-
ment of AHREs, especially with regard to prophylactic
treatment with OACs are still matter of debate.
Although CIED-detected AHREs are associatedwith a 2.0-
fold to 2.5-fold increase in stroke risk compared with
patients without these arrhythmias,28,34,35,37 the absolute
risk of stroke among these patients is lower than the risk
among patients with clinical AF.27 Moreover, CIED-detected
AHREs may occur with temporal dissociation with stroke
events, thus suggesting that they may represent a marker,
rather than a risk factor for stroke.
The controversy on the use of anticoagulants in patients
with AHREs/subclinical AF arises from the lack of robust
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scientific data, which in turn translates into a heteroge-
neous clinical management of patients and the potential
risk of bleeding due to anticoagulant therapy.5 A recent
survey has clearly underlined that there is an important
heterogeneity in the perception of the thrombo-embolic
risk associated with AHREs of different durations.56 The
burden threshold of AHREs that physicians used as a cut-off
to start an anticoagulant was extremely variable too. The
decision to prescribe an anticoagulant depended on the
overall clinical scenario and in particular on the presence
of a previous stroke. This remarkable heterogeneity in the
approach to the patient, from a diagnostic, therapeutic
and screening point of view, is also highlighted by a previ-
ous survey conducted by Dobreanu et al.57 In particular,
physicians showed a greater propensity to prescribe antico-
agulant therapy in patients with multiple and longer AHREs
and higher CHA2DS2-VASC score.
57
Although the threshold at which it is appropriate to initi-
ate oral anticoagulation in patients at risk is not defined,
data from literature indicate that the risk of stroke is surely
markedly increased when the duration of subclinical AF/
AHRE is longer than 24 h, as shown by an analysis of ASSERT
data.53 Two randomized trials, ARTESiA58 and NOAH-AFNET
6,59 are currently exploring the potential benefits of non-
vitamin K antagonists in the specific setting of AHREs.58,59
In Table 1, the main characteristics of these two ongoing
trials are shown.58,59
While waiting for the results of these randomized trials,
decision-making on oral anticoagulation has to consider in-
dividualization of decision-making and monitoring on top
of clinical risk stratification based on CHA2DS2VASc.
16
Patients with subclinical AF/AHRE show a substantial
dynamicity with transitions from lower to higher AF burden
categories depending on the AF burden at first detection
and CHADS2 score.
41 The longer the amount of AF burden
at first detection, the higher the probability of a faster
transition to an AF burden >23–24h, the threshold that in
literature has been reported to be associated with an im-
portant increase in the risk of associated stroke.53
In the absence of direct evidence, which will be avail-
able after completion of the two ongoing RCTs, ARTESiA58
and NOAH-AFNET 6,59 some considerations can be done for
addressing clinical decision-making in patients with AHRE:
• There is need for individualized decision-making, tak-
ing into account risk stratification for stroke, using
CHA2DS2VASc in combination with the amount of
detected AF burden. Even if CHA2DS2VASc was previ-
ously validated in the setting of clinical AF, and not in
the setting of AHRE, characterized by a less pro-
nounced increase in the risk of stroke as compared to
non-AF subjects,27 it may be used as a reference
with the aim to identify, even in this context,
‘truly low-risk patients’; in combination with device-
detected AF burden, that in many observational
studies appears to modulate the observed event
rate of stroke during follow-up, especially in non-
anticoagulated patients.49,60,61 The combination of
higher AHREs burden and higher CHA2DS2VASc score
allowed to identify subgroups of patients with an
event rate of stroke >1%/year, currently accepted as
a valuable threshold for prescription of OAC and spe-
cifically of non-vitamin k antagonists OACs.61
• At present, the wide variability in the perceptions of
the role of OAC in AHREs56 translates into variable
rates of OAC initiation after device-detected subclini-
cal AF, even for episodes that last >24 h.40,56 In a
large-scale observational study, it was found that
the strongest association of OAC with reduction in
stroke was observed for device-detected AF >24 h
Table 1 ARTESiA and NOAH trials: comparison of the two studies
Feature ARTESiA58 NOAH59
Planned number of patients to enrol 4000 3400
Double-blind, randomized, controlled trial Yes Yes
Inclusion if cardiac implanted electronic
device-detected AHRE 6 min
Yes Yes
Inclusion if atrial fibrillation detected by
implanted loop recorder 6 min
Yes No
Exclusion if single episode of AHRE >24 h Yes No
Exclusion if AF at baseline 12-lead ECG Yes Yes
CHA2DS2VASc score for inclusion 4 2
Active drug Apixaban 5.0 mg or 2.5 mg twice daily Edoxaban 60 mg or 30 mg daily
Comparator Aspirin 80 mg daily Usual care: Placebo or Aspirin 100 mg
daily (if clinically indicated)
Primary endpoints Stroke or systemic embolism, bleeding Composite of stroke, systemic embolism,
and cardiovascular death
Secondary endpoints Ischaemic stroke, myocardial infarction,
cardiovascular, and all-cause mortality,
composites
Components of composite, all-cause
death, and others
Censoring if single episode of AHRE >24 h Yes No
Study protocol publication Lopes et al.58 Kirchhof et al.59
AHRE, atrial high rate episode.
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(HR 0.27 after propensity-score adjustment)40 and this
finding is noteworthy, even despite all the limitations
of uncontrolled studies. It has to be stressed that most
of the uncertainty for management of AHRE with OAC
is for AHRE <24 h53 and, as a matter of fact, patients
with AHRE >24 h are not included in ARTESiA58 and
will be only a subgroup of patients enrolled in NOAH-
AFNET 659 (Table 1), so decision-making for AHREs >24
h will remain, even in the next future, largely depen-
dent on clinical judgement, without a dedicated con-
trolled study.
• In all the patients with AHRE modifiable stroke risk
factors should be identified and managed in each
patient.5
• Patients with subclinical AF/AHRE may develop atrial
tachyarrhythmias lasting more than 24 h or clinical AF
and therefore careful monitoring of these patients is
needed, even considering remote monitoring to re-
duce the time to action62,63 especially with longer
AHRE and higher risk profile. As soon as the clinical
pictures appears to be modified (new symptoms, such
as palpitations or even light-headedness, dyspnoea, or
fatigue) device interrogation coupled with a 12-lead
ECG (to detect ‘clinical’ AF) is recommended.
According with the 2020 ESC guidelines,5 individualized
decision-making has to consider the risk of stroke (to be
reassessed regularly) and also the AHRE/subclinical AF bur-
den, thus resulting in an integrated assessment with vari-
able weight of AHRE, from an ‘innocent bystander’ to an
important and evolutive finding, associatedwith a substan-
tial risk of stroke/thromboembolism. As a result of an inte-
grated, individual and clinically-guided assessment, use of
OAC, preferentially non-vitamin K antagonists OACs, may
be justified in selected patients, such as patients with lon-
ger durations of AHRE/subclinical AF, in the range of sev-
eral hours or 24h, with no doubts on AF diagnosis after
device tracing analysis and with an estimated high/very
high individual risk of stroke, accounting for the antici-
pated net clinical benefit, and the informed patient’s pref-
erences5 (Figure 5).
Conclusion
AHREs detection during CIEDs follow-up in patients with no
history of clinical AF is frequent and it will be even more
frequent in the future. AHREs are associated with an in-
creased thrombo-embolic risk which, although it is lower
than that of clinical AF, is not negligible. The thrombo-
embolic risk increases with increasing duration of AHREs.
Continuous monitoring of patients, preferably via remote
monitoring, is of paramount importance to promptly inter-
cept the evolution towards a high burden of AHRE or to-
wards clinical AF. Unfortunately, the lack of high-quality
scientific evidences on the topic is reflected in the hetero-
geneity of physicians’ clinical management of AHREs. The
long-awaited results of the ARTESiA58 and NOAH-AFNET 659
studies are likely to better define the role of anticoagulant
therapy in patients with AHREs <24 h and reduce the
uncertainties that currently surround the clinical manage-
ment of these patients. In the meantime, in the presence
of AHRE/subclinical AF, with confirmation of diagnosis at
device tracing analysis, individualized decision-making is
needed, considering the risk of stroke (to be reassessed
regularly) and also AHRE/subclinical AF burden. The use of
oral anticoagulation, preferentially non-vitamin K
Figure 5 Clinical management approach to CIED-detected AHREs according to the ESC Guidelines. From ref.,5 with permission. AF, atrial fibrillation;
AHRE, atrial high rate episode; OAC, oral anticoagulant; SCAF, subclinical atrial fibrillation.
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antagonist OACs, may be justified in selected patients,
such as patients with longer durations of AHRE/subclinical
AF, in the range of several hours or 24h, with no doubts
on AF diagnosis after device tracing analysis and with an es-
timated high/very high individual risk of stroke, accounting
for the anticipated net clinical benefit, and after appropri-
ate patient information.
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47. Pastori D, Miyazawa K, Li Y, Székely O, Shahid F, Farcomeni A, Lip
GYH. Atrial high-rate episodes and risk of major adverse cardiovas-
cular events in patients with cardiac implantable electronic devices.
Clin Res Cardiol 2020;109:96–102.
48. Wong JA, Conen D, Van Gelder IC, McIntyre WF, Crijns HJ, Wang J,
Gold MR, Hohnloser SH, Lau CP, Capucci A, Botto G, Grönefeld G,
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